Friday, July 10, 2026

pharma · Multiple Myeloma · generalized myasthenia gravis · RNAC

Cartesian Therapeutics

Cartesian Therapeutics is a pharma organization headquartered in Frederick, USA. It trades on NYSE under ticker RNAC. Primary therapeutic focus areas include Multiple Myeloma, generalized myasthenia gravis, Myasthaenia G

7495 New Horizon Way, Frederick, Maryland 21703, US HQ
2016 Founded
89 Employees
Public company Type
RNAC · NYSE Ticker
Company details
Status
Public
HQ
7495 New Horizon Way, Frederick, Maryland 21703, US
Founded
2016
Employees
89
Programs
12
Drugs
4
Patents
4
Clinical program

Placebo to Descartes-08, Descartes-08

Phase 3 · small molecule · generalized myasthenia gravis

Placebo to Descartes-08, Descartes-08 for generalized myasthenia gravis is a Phase 3 program (small_molecule) at Cartesian Therapeutics with 1 ClinicalTrials.gov record(s).

← All Cartesian Therapeutics projects Phase 3 small molecule active

Internal code RNAC-MG-002 (AURORA)

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
Cartesian Therapeutics
Phase
Phase 3
Modality
small_molecule
Indication
generalized myasthenia gravis
Status
active
Trials
1